PODD Insulet Corporation

Q2 2025 10-Q

Filed: Aug 7, 2025Period ending Jun 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Insulet Corporation (PODD) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Risk Factors

• No new or changed risk factors since 2024 10-K as stated in 10-Q risk factors section
• Carried-forward regulatory risk includes compliance with FDA medical device regulations and post-market surveillance

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$649M

▲ +32.9% YoY▲ +14.1% QoQ

Net Income

$23M

▼ -88.1% YoY▼ -36.4% QoQ

Gross Margin

69.7%

▲ +194bp YoY▼ -220bp QoQ

Operating Margin

18.7%

▲ +748bp YoY▲ +305bp QoQ

Net Margin

3.5%

▼ -3514bp YoY▼ -276bp QoQ

EPS (Diluted)

$0.32

▼ -87.6% YoY▼ -36.0% QoQ

Operating Cash Flow

$197M

▲ +103.6% YoY▲ +208.0% QoQ

Source: XBRL data from Insulet Corporation Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Insulet Corporation Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Insulet Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.